Bausch + Lomb Q2 revenue beats expectations, raises guidance

Bausch + Lomb

30/07/2025 12:07

Overview

Bausch + Lomb Q2 revenue of $1.278 bln beats analyst expectations

Adjusted EPS for Q2 meets analyst estimates, per LSEG data

Adjusted EBITDA for Q2 exceeds analyst expectations, per LSEG data

Outlook

Bausch + Lomb raises full-year 2025 revenue guidance to $5.050 bln - $5.150 bln

Company expects 5% - 7% constant currency revenue growth for full-year 2025

Full-year 2025 adjusted EBITDA guidance raised to $860 mln - $910 mln

Result Drivers

VISION CARE GROWTH - Revenue in Vision Care segment increased by 8%, driven by strong sales in dry eye portfolio and contact lenses

SURGICAL SEGMENT CHALLENGES - Surgical segment growth of 3% was impacted by voluntary recall of enVista IOL products

PHARMACEUTICALS DECLINE - Pharmaceuticals segment revenue decreased by 1% on a constant currency basis due to pricing pressures and decline in U.S. Generics business

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$1.28 bln
$1.26 bln (11 Analysts)
Q2 Adjusted EPS
Meet
$0.07
$0.07 (12 Analysts)
Q2 EPS
-$0.18
Q2 Adjusted Net Income
Beat
$25 mln
$21.80 mln (9 Analysts)
Q2 Net Income
-$62 mln
Q2 Adjusted EBITDA
Beat
$191 mln
$187.50 mln (10 Analysts)
Q2 Operating Income
-$11 mln


Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 5 "strong buy" or "buy", 7 "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."

Wall Street's median 12-month price target for Bausch + Lomb Corp is $15.50, about 5.5% above its July 29 closing price of $14.65

Press Release: ID:nBwbK4TMVa

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)